Q2
BLTE — Q2 2026 Financial Report Analysis
Belite Bio's Q2 2026 net loss widened to $28.4M as it built a launch team ahead of a Feb 12, 2027 FDA decision on tinlarebant for Stargardt disease, while $780M in cash and Treasuries leaves financing far from the near-term risk.